Valerius Biopharma

Valerius Biopharma AG is a Swiss biopharmaceutical company focused on developing specialty biosimilars as alternatives to high-priced biologics. The company's primary mission is to make treatments for severe, life-threatening, and rare diseases more affordable and accessible to patients worldwide. Valerius Biopharma's product pipeline consists of four biosimilar products in various stages of development, including two orphan and two non-orphan drugs. These biosimilars are being developed according to stringent regulatory standards to enable global access.

The company's approach involves creating interchangeable treatment options for high-priced biologics. Valerius Biopharma's team comprises scientists and experts with extensive experience in biopharmaceutical and biosimilar compound development, as well as clinical and regulatory expertise. This interdisciplinary team combines decades of experience from the biotechnology and biosimilar industry, leveraging their knowledge in process science, protein complexity, and regulatory requirements to develop their products.

Key customers and partnerships

In May 2018, Valerius Biopharma entered into a collaboration with Catalent Pharma Solutions for the development and manufacture of its biosimilar products. Under this partnership, Catalent Biologics agreed to provide cell line development and support cGMP manufacturing activities from Phase 1 through to commercial stages at its biologics manufacturing facility in Madison, Wisconsin. The collaboration utilizes Catalent's proprietary GPEx technology for creating high-performance, stable production cell lines in various mammalian host cells.